NCT05171816 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

January 22, 2024

Study Completion Date

April 28, 2026

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

olaparib

300 mg (2 x 150 milligrams (mg) tablets) twice daily

DRUG

abiraterone acetate

1000 milligrams (mg) once daily

Trial Locations (26)

100034

Research Site, Beijing

100050

Research Site, Beijing

100142

Research Site, Beijing

100191

Research Site, Beijing

100730

Research Site, Beijing

110001

Research Site, Liaoning

130012

Research Site, Jilin

130021

Research Site, Jilin

200032

Research Site, Shanghai

200040

Research Site, Shanghai

310009

Research Site, Zhejiang

310014

Research Site, Zhejiang

315000

Research Site, Ningbo

330006

Research Site, Nanchang

400038

Research Site, Chongqing

410008

Research Site, Hunan

410013

Research Site, Hunan

430030

Research Site, Hubei

450008

Research Site, Henan

510180

Research Site, Guangzhou

510515

Research Site, Guangzhou

550002

Research Site, Guizhou

610041

Research Site, Sichuan

610072

Research Site, Sichuan

710061

Research Site, Xi'an

2100008

Research Site, Nanjing